Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Published:2024-08 Issue:8 Volume:25 Page:989-1002
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wu Yi-Long,Guarneri Valentina,Voon Pei Jye,Lim Boon Khaw,Yang Jin-Ji,Wislez Marie,Huang Cheng,Liam Chong Kin,Mazieres Julien,Tho Lye Mun,Hayashi Hidetoshi,Nhung Nguyen Viet,Chia Puey Ling,de Marinis Filippo,Raskin Jo,Zhou Qinghua,Finocchiaro Giovanna,Le Anh Tuan,Wang Jialei,Dooms Christophe,Kato Terufumi,Nadal Ernest,Hin How Soon,Smit Egbert F,Wermke Martin,Tan Daniel,Morise Masahiro,O'Brate Aurora,Adrian Svenja,Pfeiffer Boris M,Stroh Christopher,Juraeva Dilafruz,Strotmann Rainer,Goteti Kosalaram,Berghoff Karin,Ellers-Lenz Barbara,Karachaliou Niki,Le Xiuning,Kim Tae Min

Funder

Merck Healthcare KGaA

Publisher

Elsevier BV

Reference33 articles.

1. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer;Chmielecki;Nat Commun,2023

2. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers;Choudhury;J Thorac Oncol,2023

3. Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib;Yu;Proc Am Soc Clin Oncol,2023

4. Tepotinib Treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial;Mazieres;JAMA Oncol,2023

5. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial;Wu;Lancet Respir Med,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment;International Journal of Molecular Sciences;2024-08-22